Anavex Life Sciences Corp (AVXL)

[XenaLives]

To be totally accurate - McFarlane stated that he expected to begin enrollment of the adaptive P2/3 in early 2017. He mentioned a base of 300 persons, which concurs with other info we have gotten from the company.

The P2 part will be final optimization and testing of dosage, P3 will morph out of P2 once that is achieved.

In the mean time we continue to have long term results from the 25 patiens in the P2a.

The cumulative data from all of these trials will result in early approval if the response of 25% or more of the three hundred remotely resembles the "strong responders" from P2a.

Before the end of 2017... IMO of course.